Study Reveals Structure of Tuberculosis Enzyme, Could Offer Drug Target
November 3rd 2015A team of scientists, including several from the U.S. Department of Energy’s Argonne National Laboratory, have determined the structures of several important tuberculosis enzymes, which could lead to new drugs for the disease.
Professor Addresses How the Ebola Scare Stigmatized African Immigrants in the U.S.
November 2nd 2015The deadly Ebola virus outbreak in West Africa also took its toll socially on one of the fastest growing populations in the United States, African immigrants. Guy-Lucien Whembolua, a University of Cincinnati assistant professor of Africana studies, leads an analysis of national news coverage of the Ebola scare in a poster presentation on Nov. 2 at the 143rd American Public Health Association (APHA) Annual Meeting and Expo in Chicago.
The Infection Preventionist's Role in Construction and Renovation: Before, During and After
November 2nd 2015The infection preventionist’s involvement in construction and renovation projects goes far beyond daily rounding. It is crucial that IPs be involved prior to construction during the concept and planning phases, as well as after construction has completed, and prior to occupancy. It takes a multi-disciplinary team to ensure that construction and renovation projects will serve both form and function of the completed needs of the space. The IP brings an infection-related mitigation skill set that serves throughout the continuum of this process.
WHO Mobilizes 510,000 Doses of Oral Cholera Vaccine to Help Control Outbreak in Iraq
November 2nd 2015An estimated 250,000 displaced persons will be targeted during the oral cholera vaccine (OCV) campaign to help control cholera outbreak in Iraq. The World Health Organization (WHO) has mobilized 510,000 doses of OCV, and the two-dose campaign is part of a strategy to prevent cholera transmission in high-risk areas and avert a potentially large-scale cholera outbreak in the 62 camps for refugees and internally displaced people.
Scientists Demonstrate a Way to Reduce the Ability of Ebola Virus to Exit a Host Cell and Spread
October 30th 2015The Ebola virus acts fast. The course of infection, from exposure to recovery, or death, can take as little as two weeks. That may not leave enough time for the immune system to mount an effective response. The goal of some antiviral therapies, therefore, is to buy more and give the immune system a leg up on the virus. A new study led by Bruce Freedman and Ronald Harty in the Department of Pathobiology of the University of Pennsylvania School of Veterinary Medicine demonstrates a way to do that, by reducing the ability of the virus to exit a host cell and spread. Their work showed that blocking a calcium-signaling pathway could inhibit not only the Ebola virus, but also Marburg, Lassa and Junin viruses, all sources of deadly infections.
Researchers' Discovery Could Be Key to Developing a Vaccine Against Toxoplasma
October 29th 2015Toxoplasma gondii is a common parasite which causes the development of fatal encephalosis or pneumonia in immunodeficient patients under treatment of AIDS or cancer. Pregnant women who are infected may suffer a miscarriage or the newborn child may suffer from a congenital disease. Currently, a toxoplasma vaccine for humans is not available. Using experimental animals such as mice, basic research for developing an inactivated vaccine is underway.
Biology-Based Field of Study Represents New Frontier for Infectious Diseases Discovery
October 29th 2015Saint Louis University’s Vaccine and Treatment Evaluation Unit has received a five-year, $5.8 million contract from the National Institutes of Health to support an “omics” research initiative to study the safety and effectiveness of vaccines and other ways to fight infectious diseases.